Novartis initiates Phase 2 study on Monte Rosa's MRT-6160 for Sjogren's disease
Monte Rosa Therapeutics announced a $50 million milestone payment from collaborator Novartis regarding a global Phase 2 clinical study of MRT-6160 for Sjogren's disease, validating the QuEEN platform's potential.
AI-generated summary for informational purposes only. Always verify against the original filing. Not investment advice. BriefTape is not a registered investment adviser.
Get real-time financial news in your trading bot or app
GET FREE KEY — 10,000 calls/day